Citi keeps a Buy rating on Incyte (INCY) with an $88 price target after the company presented data from its pivotal Phase 3 TRuE-PN1 trial ...
Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...
Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback